The Sanguine Difference
By simplifying the patient donation process, we have built a highly-engaged group of donors for minimally-invasive biospecimens.
Our Success In Numbers
2000+
Studies
Completed
15,000+
Home Visits Completed
25+
Top Pharma
Clients
100+
Nonprofit Organization Partnerships
70,000+
Patient Member Community
How the Legacy Indirect Model Stacks Up Against Ours
- Patient Access and Engagement
- Strategies for reach, recruitment, retention
- Geographic and demographic diversity
- Diversity of disease states
- Patient Centricity
- Study Design Capabilities
- Sample collection
- Participant retention
(longitudinal studies) - Patient Data
- Post-collection processing
- Clinically Relevant Annotated Specimens
- Sample integrity
- Biospecimen and data owner
- Longitudinal sampling
- Simultaneous collection of multiple specimen types
- Large volume collection (≤180 mL)
- Patient-reported outcomes data
(PRO, ePRO) - Same-day sample collection and delivery
- Integrated FHIR and C-CDA electronic health record data
- Specialty Biospecimen Collection
- Leukopaks (leukocyte-enriched apheresis products)
- Healthy specimens collected at client’s facilities
Direct Patient Access
Sanguine Model
- Patient Access and Engagement
- Strategies for reach, recruitment, retention Mobile, virtual, flexible
- Geographic and demographic diversity Nationwide, urban or rural
- Diversity of disease states Broad, multi-faceted
- Patient Centricity Engaged homegrown communities
- Study Design Capabilities
- Sample collection Prospective
-
Participant retention
(longitudinal studies) High retention rates >95% - Patient Data FHIR and C-CDA electronic health records, demographics, ability to add surveys, questionnaires, and outcomes
- Post-collection processing Customize parameters and procedures
- Clinically Relevant Annotated Specimens
- Sample integrity
- Biospecimen and data owner
-
Longitudinal sampling
- Simultaneous collection of multiple specimen types
- Large volume collection (≤180 mL)
-
Patient-reported outcomes data
(PRO, ePRO) - Same-day sample collection and delivery
- Integrated FHIR and C-CDA electronic health record data
- Specialty Biospecimen Collection
- Leukopaks (leukocyte-enriched apheresis products)
- Healthy specimens collected at client’s facilities
Indirect Patient Access
Biobanks, Others
- Patient Access and Engagement
- Strategies for reach, recruitment, retention Confined, brick and mortar
- Geographic and demographic diversity Limited by access to medical facility
- Diversity of disease states Typically oncology-focused
- Patient Centricity Third-party mediated, transactional
- Study Design Capabilities
- Sample collection Retrospective
-
Participant retention
(longitudinal studies) Low or no retention - Patient Data Often limited to demographics or possibly medical records
- Post-collection processing Limited to how specimens were initially collected
- Clinically Relevant Annotated Specimens
- Sample integrity
- Biospecimen and data owner
-
Longitudinal sampling
- Simultaneous collection of multiple specimen types
- Large volume collection (≤180 mL)
-
Patient-reported outcomes data
(PRO, ePRO) - Same-day sample collection and delivery
- Integrated FHIR and C-CDA electronic health record data
- Specialty Biospecimen Collection
- Leukopaks (leukocyte-enriched apheresis products) Specialty vendors
- Healthy specimens collected at client’s facilities
Access challenging, hard-to-collect samples
Sanguine's unique patient-centric approach to biospecimen collection gives researchers access to rare patient populations and complex study designs such as event-based collection, longitudinal collections, and more.
Are you a researcher?
Find out how Sanguine can accelerate your study.